(Q38410318)

2 September 2017

Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension (English)

1 reference

2 September 2017

0 references

8

Johann Bauersachs

1 reference

2 September 2017

Laurent Calvier

1

1 reference

2 September 2017

Ekaterina Legchenko

2

1 reference

2 September 2017

Lena Grimm

3

1 reference

2 September 2017

Hannes Sallmon

4

1 reference

2 September 2017

Adam Hatch

5

1 reference

2 September 2017

Brian D Plouffe

6

1 reference

2 September 2017

Christoph Schroeder

7

1 reference

2 September 2017

Shashi K Murthy

9

1 reference

2 September 2017

Georg Hansmann

10

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 March 2016

1 reference

2 September 2017

1 reference

2 September 2017

102

1 reference

2 September 2017

5

1 reference

2 September 2017

390-396

1 reference

Relevant issues in the pathology and pathobiology of pulmonary hypertension

2 September 2017

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Pulmonary arterial hypertension: challenges in translational research and a vision for change

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Circulating biomarkers in pulmonary arterial hypertension: update and future direction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

The potential of biomarkers in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Role of galectin-3 in human pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Aldosterone mediates cardiac fibrosis in the setting of hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2015-308365

10.1136/HEARTJNL-2015-308365

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference